Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes

NH Lee and EE el-Fakahany

Department of Pharmacology and Toxicology, University of Maryland School of Pharmacy, Baltimore.

The purpose of our study was to investigate the interactions of allosteric antagonists at the individual m1, m2 and m3 muscarinic receptor subtypes. This was achieved through the use of transformed Chinese hamster ovary cells stably expressing the rat m1 or m3 receptor genes. A homogeneous population of the m2 subtype was obtained from rat heart tissue. Our data indicate that the cardioselective antagonists (gallamine, methoctramine, AF-DX 116 and himbacine) display the following rank order of potency for both displacing ligand binding to the primary site on the receptor and allosterically decelerating ligand dissociation: m2 greater than m1 greater than m3. Schild analysis showed the following rank order of the magnitude of gallamine's cooperative interactions with the three receptor subtypes: m3 greater than m1 greater than m2. By comparison, the ion-channel blockers (verapamil, phencyclidine and quinidine) exhibited a rank order of potency for cooperative effects similar to that of cardioselective antagonists; however, these blockers did not show appreciable specificity in their interaction with the receptor primary binding site. There was a lack of correlation between the displacement of ligand binding and the allosteric potencies of the allosteric antagonists at each of the three muscarinic receptor subtypes, thus revealing the complex nature of interaction (both competitive and allosteric) between many of these compounds with the muscarinic receptor. Despite the fact that the majority of allosteric muscarinic antagonists are also K+ channel blockers, the use of pertussis toxin did not support the notion that this channel represents the allosteric site coupled to the receptor.

Volume 256, Issue 2, pp. 468-479, 02/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. S. Redka, L. F. Pisterzi, and J. W. Wells Binding of Orthosteric Ligands to the Allosteric Site of the M2 Muscarinic Cholinergic Receptor Mol. Pharmacol., September 1, 2008; 74(3): 834 - 843. [Abstract] [Full Text] [PDF]

				M. R. Dowling, J. M. Willets, D. C. Budd, S. J. Charlton, S. R. Nahorski, and R. A. J. Challiss A Single Point Mutation (N514Y) in the Human M3 Muscarinic Acetylcholine Receptor Reveals Differences in the Properties of Antagonists: Evidence for Differential Inverse Agonism J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1134 - 1142. [Abstract] [Full Text] [PDF]

				C. Fruchart-Gaillard, G. Mourier, C. Marquer, A. Menez, and D. Servent Identification of Various Allosteric Interaction Sites on M1 Muscarinic Receptor Using 125I-Met35-Oxidized Muscarinic Toxin 7 Mol. Pharmacol., May 1, 2006; 69(5): 1641 - 1651. [Abstract] [Full Text] [PDF]

				X.-P. Huang, S. Prilla, K. Mohr, and J. Ellis Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide Mol. Pharmacol., September 1, 2005; 68(3): 769 - 778. [Abstract] [Full Text] [PDF]

				O. Shibata, M. Saito, M. Yoshimura, M. Yamaguchi, T. Makita, and K. Sumikawa Interactions of Edrophonium with Neostigmine in the Rat Trachea Anesth. Analg., October 1, 2003; 97(4): 1059 - 1063. [Abstract] [Full Text] [PDF]

				U. Voigtlander, K. Johren, M. Mohr, A. Raasch, C. Trankle, S. Buller, J. Ellis, H.-D. Holtje, and K. Mohr Allosteric Site on Muscarinic Acetylcholine Receptors: Identification of Two Amino Acids in the Muscarinic M2 Receptor That Account Entirely for the M2/M5 Subtype Selectivities of Some Structurally Diverse Allosteric Ligands in N-Methylscopolamine-Occupied Receptors Mol. Pharmacol., July 1, 2003; 64(1): 21 - 31. [Abstract] [Full Text] [PDF]

				J. Scuvee-Moreau, J.-F. Liegeois, L. Massotte, and V. Seutin Methyl-Laudanosine: A New Pharmacological Tool to Investigate the Function of Small-Conductance Ca2+-Activated K+ Channels J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1176 - 1183. [Abstract] [Full Text] [PDF]

				S. Buller, D. P. Zlotos, K. Mohr, and J. Ellis Allosteric Site on Muscarinic Acetylcholine Receptors: A Single Amino Acid in Transmembrane Region 7 Is Critical to the Subtype Selectivities of Caracurine V Derivatives and Alkane-Bisammonium Ligands Mol. Pharmacol., January 1, 2002; 61(1): 160 - 168. [Abstract] [Full Text] [PDF]

				D. A. Hall Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation Mol. Pharmacol., April 13, 2001; 58(6): 1412 - 1423. [Abstract] [Full Text]

				A. Tsuda, O. Shibata, M. Saito, S. Hashimoto, S. Iwanaga, T. Makita, and K. Sumikawa A Dose-Response Study of Anticholinesterase Drugs on Contractile and Phosphatidylinositol Responses of Rat Trachea Anesth. Analg., January 1, 2001; 92(1): 100 - 105. [Abstract] [Full Text] [PDF]

				R. A. Leppik, S. Lazareno, A. Mynett, and N. J. M. Birdsall Characterization of the Allosteric Interactions between Antagonists and Amiloride Analogues at the Human alpha 2A-Adrenergic Receptor Mol. Pharmacol., May 1, 1998; 53(5): 916 - 925. [Abstract] [Full Text]

				C. Tränkle, I. Andresen, G. Lambrecht, and K. Mohr M2 Receptor Binding of the Selective Antagonist AF-DX 384: Possible Involvement of the Common Allosteric Site Mol. Pharmacol., February 1, 1998; 53(2): 304 - 312. [Abstract] [Full Text]

				C. Tränkle and K. Mohr Divergent Modes of Action among Cationic Allosteric Modulators of Muscarinic M2 Receptors Mol. Pharmacol., April 1, 1997; 51(4): 674 - 682. [Abstract] [Full Text]